Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Albemarle Wins Anthera Contract
February 11, 2008
| A version of this story appeared in
Volume 86, Issue 6
Albemarle has scored a contract to manufacture bulk quantities of varespladib, a cardiovascular disease drug from Anthera Pharmaceuticals that is in Phase III clinical trials. Scientists at Albemarle's South Haven, Mich., facility will optimize the production process and then manufacture the drug according to current Good Manufacturing Practices standards. Ontario-based Patheon will produce the finished tablet for the late-stage trials. Varespladib has shown promise in helping reduce inflammation and lower cholesterol levels in patients taking statin therapies.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X